Cyclophosphamide and MESNA

PreclinicalSmall molecule

Cyclophosphamide and MESNA is one of 18 small molecule programs targeting Bone Marrow Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone Marrow TransplantationActive, not recruiting

Bone Marrow TransplantationPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Bone Marrow Transplantation

#DrugCompanyPhaseTrials

Tepadina

Jazz Pharmaceuticals

Approved

9 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

52 3

Neupogen

EEastern Cooperative Oncology Group

Phase 3

23 4

Fludara

Sanofi

Phase 2

18 5

Cellcept

Roche

Phase 2

15 6

Rituxan

Roche

Phase 2

3 7

Prograf

VVeloxis Pharmaceuticals

Phase 2

12 8

Mesnex

BBaxter Healthcare Corporation

Phase 2

6 9

Campath

GGenzyme, a Sanofi Company

Phase 2

4 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Marrow Transplantation1 trial

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Terminated·TTami D. John·N/A·NCT00578344·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cyclophosphamide and MESNA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamide and MESNA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamide and MESNA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tami D. John company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTami D. John

Cyclophosphamide and MESNA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Marrow Transplantation1 trial

References

Drug Info

Quick Facts

Related News